Table 1 Demographic table of the breast cancer cohort, with clinical characteristics across subtypes

Age (n = 227)

(Mean ± S.D)

54.4 ± 12.2

56.1 ± 12.5

55.1 ± 11.9

51.8 ± 11.9

0.0635*

Early (> 50)

86 (37.9%)

29 (32.2%)

21 (36.2%)

36 (45.6%)

0.1941

Late (≤ 50)

141 (62.1%)

61 (67.8%)

37 (63.8%)

43 (54.4%)

NA

2

0

0

2

Menopausal status (n = 192)

pre

58 (30.2%)

21 (28.0%)

11 (21.6%)

26 (39.4%)

0.0992

post

134 (69.8%)

54 (72.0%)

40 (78.4%)

40 (60.6%)

NA

37

15

7

15

Grade (n = 229)

Low (I/II)

111 (48.5%)

67 (74.4.%)

25 (43.1%)

19 (23.5%)

<  0.0001

High (III)

118 (51.5%)

23 (25.6%)

33 (56.9%)

62 (76.5%)

NA

0

0

0

0

Tumor size (cT) (n = 216)

T1

66 (30.6%)

35 (40.2%)

13 (24.1%)

18 (24%)

0.2913

T2

136 (63%)

47 (54.0%)

38 (70.4%)

51 (68%)

T3

12 (5.5%)

4 (4.6%)

3 (5.6%)

5 (6.7%)

T4

2 (0.9%)

1 (1.1%)

0 (0.0%)

1 (1.3%)

NA

13

3

4

6

LN status (cN) (n = 206)

negative

65 (31.6%)

31 (36.9%)

14 (28.0%)

20 (27.8%)

0.3904

positive

141 (68.4%)

53 (63.1%)

36 (72.0%)

52 (72.2%)

NA

23

6

8

9

Clinical_Stage (n = 209)

Early(<IIB)

84 (40.2%)

41 (47.7%)

15 (30%)

28 (38.4%)

0.1185

Late(≥IIB)

125 (59.8%)

45 (52.3%)

35 (70%)

45 (61.6%)

NA

20

4

8

8

pT (primary tissue, no NACT) (n = 128)

T0

6 (4.7%)

4 (8.7%)

0 (0.0%)

2 (4.4%)

0.4153

T1

30 (23.5%)

14 (30.5%)

5 (13.5%)

11 (24.4%)

T2

85 (66.4%)

26 (56.5%)

30 (81.1%)

29 (64.4%)

T3

4 (3.1%)

1 (2.2%)

1 (2.7%)

2 (4.4%)

T4

3 (2.3%)

1 (2.2%)

1 (2.7%)

1 (2.2%)

NA/NACT_Yes

101

44

21

36

pN (primary tissue, no NACT) (n = 128)

negative

86 (67.2%)

31 (67.4%)

22 (59.5%)

33 (73.3%)

0.4119

positive

42 (32.8%)

15 (32.6%)

15 (40.5%)

12 (26.7%)

NA/NACT_Yes

101

44

21

36

pathological Stage (primary tissue, no NACT) (n = 128)

Early(<IIB)

85 (66.4%)

31 (67.4%)

21 (56.8%)

33 (73.3%)

0.2819

Late(≥IIB)

43 (33.6%)

15 (32.6%)

16 (43.2%)

12 (26.7%)

NA/NACT_Yes

101

44

21

36

LVI (n = 229)

negative

184 (80.3%)

67 (74.4%)

47 (81.0%)

70 (86.4%)

0.1426

positive

45 (19.7%)

23 (25.6%)

11 (19.0%)

11 (13.6%)

NA

0

0

0

0

NACT (n = 218)

No

142 (65.1%)

52 (62.2%)

40 (70.2%)

50 (65.8%)

Yes

76 (34.9%)

33 (38.8%)

17 (29.8%)

26 (34.2%)

NA

11

5

1

5

PCR status after NACT (n = 60)

pCR

15 (25%)

3 (11.1%)

2 (22.2%)

10 (41.7%)

0.0414

RD

45 (75%)

24 (88.9%)

7 (77.8%)

14 (58.3%)

NA

17

7

8

2

Survival outcomes

No. followed-up

219

87

54

78

Time in Months Mean (range)

22(0–172)

18(0–84)

24(0–172)

24(0–132)

Median months

14

12

14

18

# Recurred (local, distant)

18

5

3

10

# Death due to disease

6

2

0

4